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Abstract 
The molecular mass of the rabbit prolactin receptor (rbPRLR) deduced from cDNA cloning is 66 kDa. However, the molecular mass of the 
full-length receptor expressed in the insect Sf9 cells was found to be 94 kDa. In order to explain this discrepancy, we analyzed the possible 
post-translational modifications of the PRLR. St9 cells were infected with recombinant baculoviruses in the presence of tunicamycin, an inhibitor 
of N-glycosylation. Results showed that an additional = 9 kDa of the extracellular domain could be attributed to the N-glycosylation and another 
additional = 20 kDa covalent modification occurred in the cytoplasmic part of the receptor. Western blot analysis, using anti-ubiquitin antibodies, 
revealed that the rbPRLR was ubiquitinated in its cytoplasmic domain. 
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1. Introduction 
Pituitary prolactin (PRL) is a member of a polypeptide 
hormone family that includes placental lactogen and 
growth hormone (GH) [l]. PRL is involved in many 
biological functions in all vertebrates [2]. To date, two 
forms of PRL receptor have been cloned in different 
tissues and species [3-71, and recently a mutant form has 
been identified in the Nb2 cell line [8]. All these forms 
contain a common PRL binding extracellular domain 
(210 amino acids) with three potential N-linked glycosyl- 
ation sites, a short hydrophobic transmembrane segment 
(24 amino acids), but differ in the size of their cytoplas- 
mic domains. The PRL receptor shares some significant 
sequence homologies with the GH receptor. These recep- 
tors have been recently classified as members of the he- 
matopoietin cytokin receptor superfamily [9,10]. 
theless, after cloning of the cDNA, the predicted molec- 
ular mass of the rbPRLR was found to be 66 kDa [6]. 
We have previously reported the successful expression in 
Spodoptera frugiperda (SB) insect cells of a full-length 
form of the rbPRLR using a recombinant baculovirus 
vector [13]. This receptor bound PRL with a specificity 
and affinity similar to those reported for the native re- 
ceptor. However, the purified recombinant receptor had 
an apparent molecular mass of 94 kDa as determined by 
SDS-PAGE. This paradoxical size was attributed to the 
cytoplasmic domain of the PRLR. 
Although the biological effects of PRL on mammary 
cells are well documented, only limited information is 
available on the structure and the mechanism of action 
of the receptor. PRL receptors have been biochemically 
characterized from rabbit mammary gland (rbPRLR) 
with an apparent molecular mass of only 42 kDa [l 11, 
although higher forms have been reported [12]. Never- 
The aim of this study was to identify post-translational 
events that could explain this phenomenon. We studied 
the effects of tunicamycin, an N-glycosylation inhibitor, 
on the apparent molecular size of PRLR. Since previous 
sequencing of the purified GH receptor had revealed a 
covalent association with ubiquitin [ 141, we have investi- 
gated the ubiquitin immunoreactivity of all recombinant 
forms of the receptor. 
2. Materials and methods 
2.1. Materials 
*Corresponding author. Laboratoire de Pathologie Comparbe, Univer- 
sit& Montpellier II, CP 101, Place Eugine Bataillon, 34 095 Montpellier 
Cedex 5, France. Fax: (33) 67 14 46 79. E-mail: cahoreau @crit.univ- 
montp2.fr. 
Bovine and yeast ubiquitins, rabbit polyclonal anti-ubiquitin anti- 
bodies, rabbit anti-goat and goat anti-rabbit antibodies, and 3-amino- 
9-ethyl carbazol were purchased from Sigma. Tunicamycin was ob- 
tained from Boehringer-Mannheim, Germany. All other reagents were 
of analytical grade. 
2.2. Viruses and cells 
Abbreviations: PRL, prolactin; GH, growth hormone; SDS, sodium 
dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; Sf, Spodop- 
tera frugiperda; AcMNPV, Autographa californica nuclear polyhedrosis 
virus. 
Spodoptrra frugiperda cells (St9) were maintained at 28°C in TClOO 
medium supplemented with 10% foetal calf serum. Wild-type Autogra- 
pha califtirnica nuclear polyedrosis virus (AcMNPV) clone 1.2 [I 51 and 
recomdinant viruses expressing full-length (L), soluble (E), short (S) or 
cytoplasmic (I, and I,) forms of the rbPRLR were propagated and 
assayed in confluent monolayers of St9 cells as described previously 
[13]. 
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2.3. SDS-PAGE and Western immunoblotting 
Cells were infected with each recombinant baculovirus at a multiplic- 
ity of 10 pfu/cell and incubated at 28°C for 40 or 52 b. Mock-infected 
and wild-type baculovirus-infected cells were used as controls. Cells 
were collected and centrifuged for 5 min at 1000 x g. Cell extracts or 
supernatants were separated on either 12% or 8-12% gradient SDS- 
PAGE gels under reducing conditions, according to the method of 
Laemmli [16]. Proteins were transferred to nitrocellulose membranes 
and incubated with goat anti-rbPRLR polyclonal antibodies, or with 
anti-ubiquitin polyclonal antibodies. The blots were washed and incu- 
bated with rabbit anti-goat or goat anti-rabbit immunoglobulins conju- 
gated to horseradish peroxidase. Finally, after extensive washing, sites 
of antibody binding were visualized using the enhanced chemilumines- 
cence method (ECL; Amersham) or 3-amino-9-ethyl carbazol. 
2.4. Glycosylation 
Sf9 cells (1.5 x IO6 cells/ml) were infected with S, E, L, I,, I, recombi- 
nant baculoviruses. Tunicamycin (final concentration IO &ml) was 
added to the cell cultures at 7 or 20 h post-infection (pi). As controls, 
incubations and treatments were performed in the absence of tunicamy- 
tin. After 52 h incubation the cells were harvested and the proteins were 
analyzed by 8-12% SDS-PAGE, and electroblotted on to nitrocellulose. 
Recombinant proteins were detected by the goat anti-rbPRLR antibod- 
ies as described above. 
2.5. Antisera to ubiquitin 
Anti-ubiquitin serum was a kind gift from Dr. P. Mayeux (Paris). 
This antiserum was prepared as described by Hershko et al. [17]. 
Briefly, ubiquitin purified from bovine red blood cells was conjugated 
to y-globulin as immunogen with glutaraldehyde. Specific antibodies 
(P-antiserum) were induced in rabbits by immunization with denatured 
ubiquitin conjugate. Rabbit anti-ubiquitin antibodies from Sigma were 
also used (S-antiserum). 
3. Results 
3.1. N-Glycosylation of rabbit PRL receptor expressed in 
insect cells 
Since post-translational processing of PRL receptor 
involves carbohydrate modification [ 181, we investigated 
E S L 
the effects of the fungal antibiotic tunicamycin (for a 
review see [ 191) on N-glycosylation of rbPRLR expressed 
in Sf9 cells. Cells were infected with all recombinant 
baculoviruses, and tunicamycin was added at a concen- 
tration of 10 &ml at either 7 or 20 h pi. The apparent 
molecular mass (Fig. 1) of the E soluble form (lanes l-6), 
S truncated form (lanes 7-9) and L full-length receptor 
(lanes 10-12) were of about 27, 45 and 85 kDa, respec- 
tively. In respective control experiments, i.e. in absence 
of tunicamycin, molecular masses of 35, 55 and 94 kDa, 
respectively, were found. Thus, the carbohydrate moie- 
ties of L, E, and S forms isolated from insect cells ac- 
counted for 8-10 kDa. Furthermore, there was little or 
no change in the apparent total amount of recombinant 
proteins produced relative to the control. Whereas the E 
form secretion of rbPRLR was suppressed upon addi- 
tion of tunicamycin (lanes 3 and 5) both I1 and I, cyto- 
plasmic recombinant domains were still secreted into the 
medium (lanes 13, 15, 17, 19,21 and 23). In addition, the 
molecular mass of I, and I, produced with or without 
tunicamycin did not change (lanes 14, 16, l&20,22 and 
24). 
3.2. Detection of ubiquitin and ubiquitin-immunoreactive 
proteins in Sp by immunoblotting with anti-ubiquitin 
antisera 
After 48 h infection of Sl9 cells with wild-type 
AcMNPV and I, recombinant baculovirus, proteins 
from cell extracts and culture supernatants were sepa- 
rated on a 12% SDS-PAGE and subsequently blotted on 
to nitrocellulose. The blots were probed with two differ- 
ent anti-ubiquitin antisera: a commercial S-antiserum 
provided by Sigma (Fig. 2A) or P-antiserum (Fig. 2B); 
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Fig. 1. Effect of tunicamycin on the expression of recombinant proteins. St9 cells were infected with S, E, L, I,, I, recombinant baculoviruses and 
treated with (+) or without (-) tunicamycin (TUN). The medium was replaced 7 or 20 h post-infection with medium containing tunicamycin at 10 
&ml or with normal medium for control cells. At the end of the incubation period (52 h) the cells were harvested, the proteins were analyzed on 
a 820% gradient SDS-PAGE and subsequently electroblotted on to nitrocellulose membrane. The blots were probed with goat polyclonal anti- 
rbPRLR antibodies (1:lOO) and detected with horseradish peroxidase conjugated rabbit anti-goat antibodies (111000). Protein-antibody complexes 
were detected using 3-amino-9-ethyl carbazol at 200 pg/ml as substrate. The lanes contain samples from total cell lysates expressing the recombinant 
proteins: E (2,4,6), S (7,8,9), L (10,11,12), I, (14,16,8), I, (20,22,24); relevant culture media: E (1,3,5), I, (13,15,17) and I, (19,21,23), a set of molecular 
mass standards in lane M. 
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Fig. 2. Detection of ubiquitin and ubiquitin-immunoreactive proteins in Sf9 cells by immunoblotting with anti-ubiquitin antisera. Cellular extracts 
from uninfected St9 cells (lanes 1) or extracts and culture supernatants of cells infected with wild-type baculovirus (lanes 3, 4 and 6) or with I2 
cytoplasmic domain rbPRLR baculovirus (lanes 2 and 5) were prepared and analyzed as described above. Blots were probed with anti-ubiquitin S 
anti-serum (50 pus/ml) (blot A) and P anti-serum (l/1000) (blot B) and revealed with horseradish peroxidase conjugate goat anti-rabbit antibodies 
(112000). Protein-antibody complexes were detected by an enhanced chemiluminescence (ECL) method. I pg of yeast ubiquitin (Uy) and I pg of 
bovine ubiquitin (Ub) were used as controls. Bovine ubiquitin mixted with wild-type infected cell extract was run in lane 4. Molecular mass standards 
(kDa) are indicated on the left. The arrows indicate the migration of I, and polyhedrin (PH) and free ubiquitins (Uy and Ub). 
this P-antiserum was developed in rabbit using ubiquitin 
conjugated to bovine y-globulin as immunogen, result- 
ing in a high-affinity polyclonal antibody to ubiquitin. 
Its specificity was established by the addition of 1 ,ug 
ubiquitin to extracts of AcMNPV wild-type infected 
cells. As shown Fig. 2, an additional signal appeared 
(compare lanes 3 and 4). On the other hand, if P-antise- 
rum was incubated with 1 mg of bovine ubiquitin prior 
to the incubation of the nitrocellulose sheets, no signal 
of ubiquitined proteins could be detected (data not 
shown). Both antibodies recognized, with the same inten- 
sity, the ubiquitins from baker’s yeast (lanes Uy) and 
from bovine red blood cells (lanes Ub). The im- 
munoblots showed that the only proteins recognized by 
both the S- and P-antisera were ubiquitin itself (Uy and 
Ub) and I, recombinant protein (cell extracts lanes 2 and 
supernatants lanes 5). Thus, the results obtained with S 
or P anti-ubiquitin antibodies suggested that the I, cyto- 
plasmic rbPRLR corresponds to a covalent ubiquitin 
conjugate. Apart from the ubiquitin and I, recombinant 
protein, a number of other substrates were also ubiquiti- 
nated. P-Antiserum was used to detect other ubiquitin- 
immunoreactive proteins in the following experiment. 
3.3. Immunoreactivity of rbPRLR recombinant proteins 
with anti-ubiquitin P-antiserum 
Cells were infected with each of the five recombinant 
baculoviruses. At 48 h, cell extracts or culture superna- 
tants were run on a 12% SDS-PAGE gel and recombi- 
nant proteins (L, E, S, I,, IJ were detected by Western 
blot analysis. Non-infected cells and cells infected with 
wild-type baculovirus were used as controls. Im- 
munoblots using anti-rbPRLR (Fig. 3A) or anti-ubiq- 
uitin (Fig. 3B and C) antisera were carried out with the 
recombinant proteins. All recombinant proteins (12, I,, 
E, S, L) were specifically revealed using the anti-PRL 
receptor antiserum (Fig. 3A, lanes l-5), while only three 
forms (I*, I, and L) were detected with the antiserum 
generated against the ubiquitin (Fig. 3B, lanes 1, 2 and 
5). 
The strongest signal resulted from an interaction with 
the I, cytoplasmic recombinant protein; the im- 
munoreactive band was revealed both in cell extracts 
(Fig. 3B, lanel) and in the medium (Fig. 3C, lane 1). A 
signal was also detected with the I, intracellular ecombi- 
nant protein, the presence of a faint immunoreactive 
band was revealed in the cell extracts (Fig. 3B, lane 2). 
Consistently, a weak but detectable signal was observed 
with the full-length receptor (L) recombinant protein 
(Fig.3B, lane 5). No signal was detected with the E (Fig. 
3B and C, lanes 3) and S (Fig. 3B and C, lanes 4) forms 
of the receptor. 
4. Discussion 
In contrast with the predicted molecular mass of the 
fully N-glycosylated form of rbPRLR ( = 75 kDa), we 
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Fig. 3. Immunoreactivity of rbPRLR recombinant proteins with anti-ubiquitin antisera. Cell extracts (A and a) auk W, WU..___ _pematants (C) 
prepared from non infected cells (NI), cells infected with wild-type baculovirus (wt) or with Iz (lane I), I, (lane 2), E (lane 3), S (lane 4) and L (lane 
5) recombinants were analyzed as described above. The blots were probed with (A) goat polyclonal anti-rbPRLR antibody (1:2000), (B and C) rabbit 
anti-ubiquitin P antiserum (l/1000) and revealed with horseradish peroxidase conjugate (A) rabbit anti-goat antibodies (l/4000) (B and C) goat 
anti-rabbit antibodies (112000). Proteinantibody complexes were detected as described in Fig. 1. 
have recently shown that this receptor exhibited a higher 
molecular mass (94 kDa) when expressed in the bacu- 
lovirus expression system. Analysis of several deletion 
mutants [13] showed that while extracytoplasmic do- 
mains presented the expected sizes, a 20 kDa additional 
molecular mass was found for cytoplasmic regions. 
Studies with tunicamycin, an inhibitor of N-glycosyla- 
tion, revealed that the extracellular domain of the recep- 
tor contains N-linked oligosaccharides while this is not 
the case for the two intracellular truncated forms (I, and 
I,). The unglycosylated form of the full-length receptor 
(94 kDa) protein synthesized in the presence of tu- 
nicamycin has a molecular mass of 85 kDa, suggesting 
the presence of another post-translational modification. 
As previously reported for human tissue plasminogen 
activator (t-PA) expressed in insect cells [20], the secre- 
tion of the soluble (E) form of the extracellular domain 
was blocked by addition of tunicamycin. In contrast, the 
secretion of the I, and I2 cytoplasmic recombinant pro- 
teins was unaffected under these conditions. These re- 
sults suggested that the secretory pathway of cytoplasmic 
recombinant proteins through the St9 cells might be dif- 
ferent. Another post-translational modification, such as 
addition of phosphate groups or ubiquitination, may 
cause the differences between the apparent and predicted 
molecular mass. Ubiquitination is a widespread post- 
translational modification of eukaryotic cellular pro- 
teins, which is involved in many normal and pathological 
biological functions (for reviews see [21-231). 
While antibodies directed against synthetic ubiquitin 
peptides (Gift of Dr. Muller) did not recognize rbPRLR 
recombinant proteins (unpublished results), antibodies 
(P-antiserum) raised against ubiquitin conjugated to bo- 
vine y-globulin had a very strong affinity with the I, 
intracellular domain. The I, cytoplasmic domain and the 
full-length receptor reacted more weakly with these anti- 
bodies. The observed differences suggest that the epi- 
tape(s) of anti-ubiquitin antibodies are less accessible 
(likely to be masked) in these forms. From our data we 
were unable to determine the number of ubiquitin units 
associated with the receptor, and further experiments 
will be required to identify the ubiquitination site(s). Di- 
rected mutagenesis of lysine residues thought to be impli- 
cated in the ubiquitin conjugation would be of great 
interest. 
Sequencing of the purified GH receptor revealed a 
covalent association with ubiquitin [14]. Interestingly, 
this ubiquitination was not found on the serum binding 
protein [24]. The significance of this ubiquitin-associa- 
tion for receptor structure and/or function remains un- 
known. It has been suggested that ubiquitin could be 
involved in the rapid receptor turnover observed in vivo 
or in mechanisms mediating receptor cleavage, and thus 
generating the binding protein [14,24]. Moreover, 
Moldrup et al. reported a higher (20 kDa) apparent 
molecular weight of GH receptor expressed in rat insuli- 
noma cells, and this was attributed to the receptor cyto- 
plasmic part. A covalent modification would occur prox- 
imally to the transmembrane domain [25]. 
The association of ubiquitin to proteins is involved in 
a great variety of cellular processes [22]. According to the 
‘tagging’ hypothesis, a major function of ubiquitin is to 
mark proteins for subsequent degradation (for a review 
see [26]). Thus, ubiquitination might serve as a means to 
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down-regulate receptors but it is possible that conjuga- 
tion of ubiquitin to certain proteins also mediates non- 
proteolytic function(s). Hence, stable ubiquitin acceptors 
have been reported, including histones H2A and H2B 
[27], actin [28], the GH receptor [14,24], and others re- 
ceptors [29,30]. Ligand-induced changes in the ubiquiti- 
nation of receptors have also recently been described 
[31,32]. Reversible attachment of ubiquitin residues to a 
protein for modulation of protein function without tar- 
geting the protein for degradation has also been sug- 
gested [33]. The role of ubiquitination of the rbPRLR is 
still unclear. Ubiquitination might be involved (i) in the 
down-regulation of the receptor or (ii) in some specific 
protein-protein interactions conferring a ‘competent 
folding’ to the receptor . 
The ability of the baculovirus expression system to 
perform the appropriate post-translational modifica- 
tions to recombinant proteins is well documented [34]. 
We have demonstrated that the full rbPRLR (i) was 
targeted to the cell membrane, (ii) bound PRL with a 
specificity and affinity similar to those reported for the 
native receptor [13], (iii) was N-glycosylated in its ex- 
tracellular domain, and (iv) was ubiquitinated in its in- 
tracellular domain. The major question is whether the 
ubiquitination we observed in infected St9 cells reflects 
a physiologically relevant association. Thus it is not pos- 
sible to claim, without direct evidence, that proteins pro- 
duced in infected insect cells cultures are identical to 
those found in differentiated tissues. Experiments using 
functional assays in mammalian cells [35] with mutant 
forms of the receptor generating ubiquitinated or non- 
ubiquitinated forms of the receptor, would give a re- 
sponse to this interesting question. 
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